GC supplementation in obese NAFLD patients reduced inflammatory biomarkers (IL-6, TNF-α, and hs-CRP), ALT, and the degree of fatty liver and increased Sirt1 compared with placebo. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.